Research
Independent analysis of SEC filings, private funds, RIAs, websites and regulatory records.
Rice Capital Fund II SEC Review: Zero Sales, Undisclosed Fees and Japan-US Venture Risks
Rice Capital Fund II, LP is a newly formed Delaware venture capital fund associated with Rice Capital, an investment platform led by entrepreneur Taro Fukuyama and focused on startup opportunities in the United States and Japan. Its September 24, 2026 SEC Form D establishes an identifiable legal issuer, general partner and investment category, but reports zero investors, zero securities sold and an indefinite offering amount, with the first sale yet to occur. A particularly important disclosure appears in the use-of-proceeds section: certain affiliates of the general partner may receive management fees or incentive allocations funded by offering proceeds, although the amounts cannot presently be estimated. This creates a direct distinction between zero reported sales compensation and the broader economics of participating in the fund. Rice Capital's website also identifies separate Fund I and Fund II general partners under a Japanese regulatory disclosure framework, making cross-border governance and the separation of investor rights central due-diligence issues. The available records establish a new private offering rather than demonstrated fund-level investment performance. Investors should examine the complete fee structure, investment allocation policies and applicable US and Japanese legal arrangements before relying on the sponsor's broader investment history.
Rice Capital Fund II, LP · CIK 0002142145Read article →
ParentConnect LLC SEC Review 2026: $100K SAFE Offering and Filing Discrepancy
ParentConnect LLC is an Illinois limited liability company formed in 2024 with an identifiable SEC filing under CIK 0002098455. Its December 1, 2025 Form D reports a $100,000 exempt offering involving a Simple Agreement for Future Equity, commonly known as a SAFE, with the entire stated amount reported sold to one investor. However, the filing contains an important inconsistency: the issuer simultaneously selected "First Sale Yet to Occur" despite reporting $100,000 sold and one participating investor. This discrepancy deserves clarification because the timing and completion of an offering are relevant to the accuracy of securities disclosures. A second material issue appears in the use-of-proceeds section, where ParentConnect estimates that $18,000 will be allocated to founder compensation through member distributions. That represents 18% of the stated offering amount, although the filing does not establish that the entire amount was actually distributed. The company's public regulatory disclosure also provides limited information about its operating business, ownership structure, financial performance and eventual conversion terms. Investors should distinguish the existence of a registered SEC filing from confirmation of the company's commercial activities, financial strength or future equity value. The central due-diligence questions concern the consistency of the filing, the economics of the SAFE agreement, the allocation of investor capital and the legal identity of any product or website presented under the ParentConnect name.
ParentConnect LLC · CIK 0002098455Read article →
CAZ Co-Investment Opportunities SEC Review: ARMADA II Fund, Fees and Investor Risks
CAZ Co-Investment Opportunities Fund, L.P. - ARMADA II Portfolio is a Delaware private equity investment vehicle connected to CAZ Investments, an established Houston-based alternative investment manager. Its May 26, 2026 SEC Form D reported $875,000 in securities sold to four investors, with the first sale occurring on May 1. The filing identifies a recognizable management structure and an existing sponsor, but it does not establish the underlying investment's identity, current valuation, audited performance or expected exit timetable. The more significant concerns emerge from CAZ's broader investment model. Its regulatory disclosures acknowledge potential conflicts involving affiliated funds, performance-based compensation, investment allocation and preferential investment access. These matters are particularly relevant to a co-investment portfolio that may provide exposure to a limited number of private assets rather than a diversified investment strategy. CAZ's institutional relationships and broader investment history offer useful sponsor context, but they cannot substitute for vehicle-specific financial evidence. The available records establish material due-diligence questions concerning fees, concentration, related-party arrangements and liquidity, without demonstrating fraud or misconduct by ARMADA II.
CAZ Co-Investment Opportunities Fund, L.P. - ARMADA II Portfolio · CIK 0002126697Read article →
EnQuanta SEC Review 2026: $10.1M Funding, Executive Payments and Security Risks
VoiceIt Technologies, Inc., operating under the EnQuanta brand, is an identifiable Delaware cybersecurity company with a September 2026 SEC Form D filing, an independently verifiable NIST cryptographic-module certification and an operating technology platform focused on quantum-resistant security. Its September 22 filing reports $10,102,979 sold to 74 investors, including nine non-accredited investors, under a Rule 506(b) exempt offering. However, the most consequential disclosure is not the fundraising total. The filing estimates that $5 million of offering proceeds have been or may be used for payments to executive officers, directors or promoters, an unusually important allocation for investors examining how their capital supports product development and company operations. The company also reports annual revenue within the $1 to $1 million range, leaving a substantial distinction between cumulative fundraising and demonstrated commercial income. EnQuanta's FIPS 140-3 certification provides independent evidence supporting a specific cryptographic module, but it does not validate every product, deployment configuration or broader commercial claim. Investors should examine the economics of the extended financing period, executive compensation, security certification boundaries, customer adoption and future funding requirements before treating the company as an established profitable cybersecurity business.
EnQuanta · CIK 0002156635Read article →
IEQ Capital Access Fund SEC Review: $20M Raise, Layered Fees and Investor Conflicts
IEQ Capital Access Fund - Private Equity Select 2026, L.P. is a Delaware private investment vehicle associated with IEQ Capital and the iCapital alternative investment infrastructure. Its April 7, 2026 SEC Form D reported $20 million in securities sold to one investor, following a first sale on March 26. This establishes a documented initial offering transaction, but it does not establish the vehicle's current net asset value, underlying portfolio, investment returns or ultimate investor distributions. The more significant research finding comes from IEQ Capital's own regulatory disclosures, which describe an Access Fund model involving iCapital management arrangements, IEQ sub-advisory compensation, underlying private investment funds and potentially multiple layers of expenses. Those disclosures also identify investment allocation conflicts and fee arrangements that can persist beyond the termination of a client's broader advisory relationship. For investors, the central question is not whether an SEC filing exists, but how much economic exposure remains after intermediary charges, underlying manager fees and fund-level expenses. The evidence supports material concerns about cost transparency, allocation fairness and liquidity; it does not establish fraud or misconduct by this particular fund.
IEQ Capital Access Fund - Private Equity Select 2026, L.P. · CIK 0002123798Read article →
AngelEye Health SEC Review 2026: $20M Offering, NICU Technology and Investor Risks
AngelEye Health, Inc. is an identifiable Delaware healthcare technology company with an SEC filing history extending to 2021 and an operating platform serving neonatal intensive care units and pediatric departments. Its September 2026 Form D listing reports $9,999,992 sold against a $20,000,010 equity offering, adding another financing event to a history of repeated private capital raising. Unlike an issuer supported only by a fundraising announcement, AngelEye has identifiable management, an operating website, hospital relationships and a documented acquisition history. Nevertheless, its expanding business introduces financial and operational uncertainties that deserve closer investigation. The company has moved beyond its original family-engagement technology into feeding management, discharge coordination and AI-assisted neonatal monitoring, creating additional requirements for product integration, patient-data security and regulatory compliance. Its private financing disclosures do not establish profitability, current cash reserves, company valuation or investor liquidity. The most consequential questions concern the relationship between continued fundraising and sustainable operating cash flow, the economics of recent acquisitions, and whether emerging AI applications can progress from research into clinically validated and appropriately authorized products.
AngelEye Health · CIK 0001844416Read article →
Valor National Security Fund I SEC Review: New Defense Investment Fund, Fees and Investor Risks
Valor National Security Fund I L.P. is a newly formed Delaware private investment vehicle associated with the established Valor Equity Partners investment platform. Its September 24, 2026 Form D provides identifiable management personnel, a Chicago business address and a recognizable institutional placement intermediary. However, the filing establishes an offering notice rather than a successful fundraising record. The issuer reported zero investors, zero securities sold and an indefinite offering amount, with the first sale yet to occur. Investors therefore cannot infer committed capital, a completed portfolio or demonstrated fund-level performance from this filing. The most important questions concern the fund's actual investment mandate, relationship with parallel vehicles, placement arrangements, fee allocation and valuation procedures. Valor's existing investment history provides useful background, but it should not be substituted for evidence about this specific fund. The filing does not itself establish misconduct, and the identified disclosure gaps are investment due-diligence concerns rather than findings of fraud.
· CIK 0002140225Read article →
Seraxis Holdings SEC Review 2026: $10M Financing, BetaNova Merger and Investor Risks
Seraxis Holdings is a U.S. biotechnology company developing stem cell-derived pancreatic islet therapies for Type 1 diabetes, with a historical SEC filing profile and a proposed merger with publicly traded Sernova Biotherapeutics. Its September 2026 financing and merger announcement provide identifiable corporate evidence, but the transaction introduces risks that are not apparent from the $10 million fundraising headline. The proposed combination would create BetaNova Biotherapeutics, bringing together Seraxis' cell-manufacturing capabilities and Sernova's Cell Pouch technology. However, completion remains subject to shareholder, court and regulatory approvals, while the financing involves convertible instruments that may affect future ownership and voting rights. The combined therapeutic platform has not yet established the intended clinical outcome in patients, and the companies remain dependent on development milestones rather than established commercial revenue. Investors should pay particular attention to the proposed ownership allocation, financing conversion terms, existing liabilities, clinical execution and future capital requirements. A documented SEC filing establishes a regulatory disclosure history, not SEC endorsement of the issuer or assurance that the merger, clinical program or planned public listing will succeed.
Seraxis Holdings · CIK 0001845486Read article →
Northforge Ventures Fund I SEC Review: New Series Fund With Three Investment Managers
Northforge Ventures Fund I is a newly formed venture-capital series vehicle whose most distinctive feature is not fundraising size but the number of investment managers explicitly identified in its first SEC filing. The Delaware LLC, organized as a series of A Master Series, LLC, filed Form D on September 17, 2026 with an indefinite offering, $0 sold, zero investors and "First Sale Yet to Occur." It relies on Rule 506(b) and Section 3(c)(1), is classified specifically as a Venture Capital Fund, and reports a nominal $1 minimum-investment field. More unusually, the filing names three separate entities as investment managers and promoters: Fourth Revolution Capital LLC, Northforge Ventures LLC and Atoms & Bits Management LLC. Alternative Financial Corporation is separately identified as administrator, with Bryan Casey signing as CEO of Alternative and manager of the applicant. The research story is therefore a multi-manager, externally administered series-fund architecture rather than a conventional standalone VC partnership controlled through one GP.
Northforge Ventures Fund I, a Series of A Master Series, LLC · CIK 0002154735Read article →
Spark Capital IX SEC Form D Review 2026: $850M Target and the $10.1M Founders' Fund Companion
SPARK'S FUND IX HAS TWO DIFFERENT FUNDRAISING STORIES
Spark Capital IX · CIK 0002123887Read article →
Greycroft Alpha SEC Form D Review 2026: $0 Launch, Rule 506(c) and a New Vehicle Inside Greycroft's AI-Growth Platform
Greycroft Alpha, L.P. is a newly formed 2026 Delaware venture capital vehicle that is easy to verify at the sponsor level but still opaque at the fund level. The June 11, 2026 Form D uses Greycroft's exact 292 Madison Avenue, 8th Floor New York headquarters and 212-756-3508 telephone number, identifies Greycroft co-founder Ian Sigalow as a director of the issuer's general partner, classifies the issuer as a venture capital fund and offers both equity and pooled investment fund interests. The filing relies on Rule 506(c) rather than the more common 506(b), selects Section 3(c)(7), reports an indefinite offering, $0 sold, zero investors, a $0 stated minimum and "first sale yet to occur." Those facts establish that Alpha was a real legal launch inside Greycroft's platform, but they do not establish that outside capital had closed or that any portfolio company had already been allocated to the vehicle. :contentReference[oaicite:1]{index=1}
Greycroft Alpha, L.P. · CIK 0002137974Read article →
Advent Partners MMPE-C SEC Review: New Mid-Market Fund Vehicle Inside Advent's $109B Global Platform
Advent Partners MMPE-C SCSp is a newly formed Luxembourg private-equity vehicle that appears to be part of Advent International's developing Mid-Market Private Equity program rather than another sleeve of the firm's $25 billion GPE X flagship fund. The September 17, 2026 Form D reports an indefinite offering, $0 sold, zero investors and "First Sale Yet to Occur," with Rule 506(b) and Section 3(c)(7) selected. Advent Mid-Market Private Equity GP S.a r.l. is identified as the general partner, while Neil Crawford is listed as an executive officer through the layered management structure. The vehicle is classified specifically as a Private Equity Fund. The central research story is therefore product architecture: Advent has created multiple Luxembourg MMPE entities during 2025–2026, secured regulatory distribution registrations in Europe and attracted at least one publicly disclosed institutional commitment to a sister vehicle, even though this particular MMPE-C issuer had not yet reported a U.S. investor or first sale.
Advent Partners MMPE-C SCSp · CIK 0002142643Read article →